Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.

Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the functions of viral HCMV glycoprotein B (gB) and the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. In this phase 2, randomized, placebo-controlled trial, we evaluated the safety and efficacy of CSJ148 for prophylaxis of HCMV in patients undergoing allogeneic hematopoietic stem cell transplantation. As would be expected in the study population, all the patients (100%) reported at least one treatment-emergent adverse event. There were 22 deaths during this study, and over 80% of the patients receiving placebo or CSJ148 developed at least one adverse event of grade 3 or higher severity. No subject who received antibody developed a hypersensitivity- or infusion-related reaction. CSJ148-treated patients showed trends toward decreased viral load, shorter median duration of preemptive therapy, and fewer courses of preemptive therapy. However, the estimated probability that CSJ148 decreases the need for preemptive therapy compared to placebo was 69%, with a risk ratio of 0.89 and a 90% credible interval of 0.61 to 1.31. The primary efficacy endpoint was therefore not met, indicating that CSJ148 did not prevent clinically significant HCMV reactivation in recipients of allogeneic hematopoietic cell transplants. (This study has been registered at ClinicalTrials.gov under identifier NCT02268526 and at EudraCT under number 2017-002047-15.)

The correlation between family cohesion and success in autistic treatment

This research project offered an overview of Autistic spectrum disorder and discussed the need for research regarding the family\u27s role in treatment. The treatment framework examined in this research project was Applied Behavioral Analysis. The study took place at the University Center for Developmental disabilities (UCDD), located at California State University San Bernardino

Senior Recital:Andrew Gerbitz, Trumpet

Kemp Recital Hall Friday Evening February 29, 2008 7:00p.m

A Performer\u27s Guide to Iosif Andriasov\u27s Concertino for Trumpet

Iosif Andriasov’s Concertino for Trumpet is an excellent candidate for study and assimilation into the standard trumpet repertoire. A significant composer of Armenian descent from the former Soviet Union, Andriasov wrote his Concerto for Trumpet in 1960 and dedicated it to Yuri Usov. Timofei Dokshizer performed it on an album released in 1978 under the Melodya label. After immigrating to the United States in 1979, the composer revised the work and retitled it as Concertino for Trumpet in 1995. IMMA Publishing Company in New York made the revised work commercially available in 2001. This paper is presented to increase awareness of this composer and his Concertino. It includes a short review of literature on major works of Soviet trumpet music, a biographical sketch of Andriasov, a discussion of the history and form of his Concertino for Trumpet, and concludes with a detailed discussion of preparation and practice techniques to allow for a successful performance of this piece

Graduate Recital: Andrew Gerbitz, Trumpet; Gloria Cardoni-Smith, Piano; April 20, 2010

Kemp Recital HallApril 20, 2010Tuesday Evening7:00 p.m

Multidecadal variability in Atlas cedar growth in northwest Africa during the last 850 years: implications for dieback and conservation of an endangered species

Widespread forest dieback is a phenomenon of global concern that requires an improved understanding of the relationship between tree growth and climate to support conservation efforts. One priority for conservation is the Atlas cedar (Cedrus atlantica), an endangered species exhibiting dieback throughout its North African range. In this study, we evaluate the long-term context for recent dieback and develop a projection of future C. atlantica growth by exploring the periodic variability of its growth through time. First, we present a new C. atlantica tree- ring chronology (1150–2013 CE) from the Middle Atlas mountains, Morocco. We then compare the new chronology to existing C. atlantica chronologies in Morocco and use principal components analysis (PCA) to isolate the common periodic signal from the seven longest available records (PCA7, 1271–1984 CE) in the Middle and High Atlas portions of the C. atlantica range. PCA7 captures 55.7% of the variance and contains significant multidecadal ( ̃95yr, ̃57yr, ̃21yr) periodic components, revealed through spectral and wavelet analyses. Parallel analyses of historical climate data (1901–2016 CE) suggests that the multidecadal growth signal ori- ginates primarily in growing season (spring and summer) precipitation variability, compounded by slow- changing components of summer and winter temperatures. Finally, we model the long-term growth patterns between 1271–1984 CE using a small number (three to four) of harmonic components, illustrating that sup- pressed growth since the 1970s – a factor implicated in the dieback of this species – is consistent with recurrent climatically-driven growth declines. Forward projection of this model suggests two climatically-favourable periods for growth in the 21st century that may enhance current conservation actions for the long-term survival of the C. atlantica in the Middle and High Atlas mountains

Human Nesidioblastosis Tissue as an Immunogen for Generation of Islet Cell Specific Monoclonal Antibodies

Peer Reviewe

Enolase Isoenzymes as Tumour Markers

Peer Reviewe